Intelligence Dashboard

BGI is the only biotech entity currently designated as a Biotechnology Company of Concern under the BIOSECURE Act, via its presence on the DoD Section 1260H list (Category A). The designation covers BGI Genomics (300676.SZ), its sequencing instrument subsidiary MGI Tech (688114.SS), and US-based subsidiary Complete Genomics. BGI's BIOSECURE risk stems not from drug manufacturing but from genomic data collection — its NIFTY prenatal testing platform processed samples from millions of pregnant women globally, and its COVID-19 testing labs operated in multiple US states. Founded by Jian Wang as part of China's contribution to the Human Genome Project, BGI has deep ties to PRC state funding and has been described in Chinese government policy documents as a 'national champion' in genomics.

Complete Genomics is a BIOSECURE-designated genomics sequencing company with dual operations in San Jose and BGI China, making it extremely high-risk for US pharma partnerships. The company specializes in next-generation sequencing technologies and genomic analysis platforms but faces complete market exclusion from US government contracts and likely partner avoidance due to national security concerns. Any BD engagement would require immediate divestiture from BGI or complete operational separation, which appears structurally impossible given the integrated business model. US pharma should avoid engagement unless Complete Genomics undergoes fundamental ownership restructuring.

MGI Tech is a Shenzhen-based genomic sequencing technology company designated under the BIOSECURE Act, making it off-limits for US pharma partnerships. The company specializes in DNA sequencing instruments and reagents, competing directly with Illumina in the genomics space. While they have strong technology capabilities in sequencing platforms, their BIOSECURE designation creates insurmountable regulatory barriers for US deals. Any engagement would require complete divestiture from Chinese operations, making partnerships commercially unviable.

Aoxiang Pharma is a Zhejiang-based CDMO with solid financial performance (¥690M revenue, ¥229M net profit in Q3 2024) focused on generic drug development and manufacturing. The company recently achieved regulatory milestones with entecavir tablets and tofacitinib citrate tablets receiving approvals, indicating active pipeline execution. Under congressional pressure regarding BIOSECURE Act compliance, creating moderate partnership risk for US pharma companies. Recent share buyback and high-tech enterprise recertification suggest financial stability and R&D investment focus.

Asymchem is China's leading small molecule CDMO with ~$1.5B revenue, serving major US pharma including Pfizer (Paxlovid API supplier), BMS, and Lilly. Founded in 1995 by Hao Hong, the company has deep API manufacturing capabilities but faces severe BIOSECURE Act exposure as a likely Category B designation candidate. While operationally strong with proven US pharma relationships, new partnerships carry significant regulatory and political risk.

BrightGene Bio-Medical is a Suzhou-based CDMO trading on Shanghai's STAR Market with ~$180M revenue and strong profitability (15% net margin). The company faces medium BIOSECURE risk due to congressional pressure but has not been formally designated, creating deal uncertainty for US partners. Recent regulatory filings suggest active fundraising and governance strengthening, indicating potential deal readiness for partnerships requiring manufacturing scale.

Jiuzhou Pharmacy is a Zhejiang-based CDMO with strong financial performance (¥3.97B revenue, ¥631M net profit in 2024) that faces moderate BIOSECURE risk due to congressional pressure. The company demonstrates active deal-making capability through recent subsidiary drug approvals and investment activities, making it an attractive manufacturing partner for US pharma. However, BIOSECURE concerns may complicate near-term engagement strategies.

Medicilon is a Shanghai-based preclinical CRO providing drug discovery, DMPK, and safety assessment services to global biotech clients through its main operating subsidiary. The company faces significant BIOSECURE Act risk due to congressional pressure and its mainland China operations serving US pharma clients. As a service provider rather than asset developer, Medicilon offers limited pipeline value but represents the CRO sector's vulnerability to US-China decoupling in pharmaceutical services.

Pharmaron is China's top-5 CRO/CDMO with ~$1.2B revenue, offering full-spectrum drug discovery to commercial manufacturing services. The company serves major pharma clients including J&J, Novartis, and AbbVie, positioning it as a critical service provider but also making it a prime target for BIOSECURE Act designation. Founded by Boliang Lou in 2004, Pharmaron is dual-listed on HK/Shenzhen exchanges and faces high regulatory risk following the December 2024 BIOSECURE Act signing.

Porton Pharma Solutions is a Chongqing-based small molecule CDMO specializing in API and intermediate manufacturing for global pharmaceutical companies. The company faces significant BIOSECURE risk due to congressional pressure, making it a potentially problematic partner for US pharma companies despite its manufacturing capabilities. Limited public information suggests a traditionally conservative Chinese pharma company structure focused on contract manufacturing rather than proprietary drug development.

Tigermed is China's largest CRO with ~$900M revenue, providing clinical trial management services to multinational pharma companies. Founded by Xiaoping Ye in 2004, the company is publicly listed on Hong Kong Stock Exchange. While not formally designated under BIOSECURE, it faces congressional pressure and represents a significant compliance risk for US pharma partnerships given its core mainland China operations.

WuXi AppTec is the single largest BIOSECURE exposure point in the US biotech supply chain. As the world's largest pharmaceutical CRO/CDMO by client count, WuXi provides contract research, manufacturing, and testing services to an estimated 6,000+ pharmaceutical and biotech companies globally, including the majority of the top 20 pharma companies. 34 US-listed companies have explicitly named WuXi in BIOSECURE-related SEC filings. While WuXi was removed from the enacted BIOSECURE Act's named entity list (unlike BGI), it remains under sustained congressional pressure and could be designated as a BCC via OMB's Category B process when the list is published by December 2026. Ge Li, the Columbia-trained chemist who founded WuXi in 2000, controls approximately 25% of voting rights through a complex holding structure spanning Cayman, BVI, and mainland China entities.

WuXi Biologics is China's leading CDMO with world-class biologics manufacturing capabilities and an integrated platform spanning discovery to commercial production. The company has historically been deal-friendly with Western pharma but faces significant BIOSECURE Act pressure that could restrict US partnerships. Strong technical capabilities and global manufacturing footprint make it an attractive partner, but regulatory headwinds create substantial deal execution risk.

WuXi XDC is a Shanghai-based CDMO specializing in antibody-drug conjugates (ADCs), listed on Hong Kong exchange. As part of the broader WuXi ecosystem, the company faces significant BIOSECURE Act pressure that could restrict US partnerships. Despite strong technical capabilities in ADC manufacturing, US pharma should proceed with extreme caution given regulatory headwinds and potential future designation.

3SBio is a Shenyang-based biotech that just completed one of the largest China-to-US licensing deals in history, licensing a bispecific antibody to Pfizer for $1.25B upfront and up to $4.8B total. The company demonstrates strong deal-making capability and pipeline quality, evidenced by securing the highest upfront-to-total ratio (26%) among mega-deals. With clear BIOSECURE status, 3SBio represents a lower-risk partnering opportunity for US pharma seeking to access innovative Chinese biotech assets.

There appears to be a data error - AbbVie is a major US pharmaceutical company headquartered in North Chicago, not a Chinese entity. AbbVie is a Fortune 500 company spun off from Abbott in 2013, known for blockbuster drugs like Humira and Skyrizi. As a US-domiciled company, AbbVie has no BIOSECURE Act exposure and would typically be an acquirer rather than target in BD transactions. This profile request may have incorrect entity identification.

Abbisko Therapeutics is a Hong Kong-listed Chinese biotech with clear BIOSECURE status, making it a viable partner for US pharma. However, limited public disclosure on pipeline assets, management team, and recent corporate activities suggests either early-stage development or strategic opacity. The Shanghai headquarters and Hong Kong listing indicate likely VIE structure requiring careful due diligence. Without visible pipeline data or recent deal activity, engagement should focus on information gathering before deal evaluation.

Adagene is a dual-headquartered (Suzhou/San Diego) biotech focused on novel antibody therapeutics with NASDAQ listing (ADAG) providing transparency for US investors. The company appears deal-ready with clear BIOSECURE status, though limited public information on pipeline specifics requires deeper due diligence. Recent 10-K filing indicates standard VIE structure for China-based biotechs, requiring careful contract review but not prohibitive for partnerships.

Akeso is a Chinese biotech with first-in-class ivonescimab (PD-1/VEGF bispecific) that beat Keytruda head-to-head in lung cancer trials - a historic achievement. The company has a Nov 2026 PDUFA date and represents a rare opportunity to partner with a China-originated biologic that has proven superiority over a Western blockbuster. Clear BIOSECURE status with standard Cayman/mainland structure makes it dealable for US pharma.

Alphamab Oncology is a Suzhou-based biotech focused on oncology therapeutics, trading on Hong Kong Stock Exchange. The company appears to have clear BIOSECURE status, making it potentially attractive for US partnerships without regulatory complications. Limited public information on recent corporate activities and leadership suggests either a low-profile operational phase or potential data gaps requiring deeper due diligence.

Antengene is a dual-headquartered (Shanghai/San Diego) biotech with a clear BIOSECURE status, making it an attractive partner for US deals. The company's bi-continental structure suggests strong Western market orientation and regulatory experience. With Hong Kong listing (6996.HK), it has public market access for funding partnerships, though limited public information suggests conducting thorough due diligence on pipeline assets and management depth.

Ascentage Pharma is a Suzhou-based biotech focused on apoptosis-targeted therapies with validated deal-making capability, evidenced by their successful Takeda partnership for olverembatinib. The company has achieved commercial success in China with their third-generation BCR-ABL TKI for CML and demonstrates strong capabilities in developing differentiated targeted therapies. BIOSECURE risk appears low given their clear status, making them an attractive partner for US pharma seeking China-originated assets.

AskGene Pharma appears to be an early-stage Chinese biotech with minimal public presence and no available pipeline or leadership information. The company presents significant due diligence challenges due to lack of transparency and public disclosures. While currently clear of BIOSECURE designation, limited visibility into operations and corporate structure creates elevated regulatory and commercial risk for US partnerships.

AstraZeneca is a major UK-based multinational pharmaceutical company with significant global operations and a strong pipeline across oncology, cardiovascular, respiratory, and immunology. The company has extensive China operations through AstraZeneca China but maintains clear BIOSECURE status with no regulatory restrictions. AstraZeneca is highly active in licensing deals and partnerships, making it an attractive but competitive BD target requiring senior-level engagement.

BeiGene is the only Chinese biotech to have built a global commercial infrastructure, with approved products (zanubrutinib/BRUKINSA) generating $2.5B+ in annual revenue across the US, Europe, and China. Unlike most Chinese biotechs that out-license to Western partners, BeiGene retains global rights and commercializes directly — making it both a competitor to and potential partner for Big Pharma. The company maintains dual listings (NASDAQ: BGNE, HKEX: 6160) and files 10-K annual reports with the SEC, providing unusually transparent corporate structure disclosure for a China-headquartered biotech. Co-founded by John Oyler (American) and Xiaodong Wang (Chinese Academy of Sciences), BeiGene's Western-Chinese dual leadership has been central to its credibility with US investors and regulators.

Beijing Biotech presents a significant information gap challenge with no publicly available data on leadership, pipeline, or corporate activities. The company's BIOSECURE-clear status provides regulatory comfort for US partnerships, but the complete lack of transparency raises substantial due diligence concerns. Without visibility into therapeutic focus areas, development programs, or management team, this entity would require extensive primary research before any meaningful BD engagement. The absence of basic corporate information suggests either a very early-stage company or potential operational/transparency issues.

Beijing Dongfang Biotech Co., Ltd. is a Chinese biotech company with limited publicly available information, presenting significant due diligence challenges for US BD teams. The company appears to be clear of BIOSECURE Act designation currently, but the lack of transparency around corporate structure, pipeline, and leadership creates elevated risk for partnership evaluation. Without detailed pipeline or recent deal activity data, assessing strategic fit and commercial potential is difficult.

Beijing Mabworks Biotech is a Chinese biotech company with limited publicly available information, presenting significant due diligence challenges for US BD teams. The company appears to focus on biologics development based on its name, but pipeline details, leadership, and corporate structure remain opaque. BIOSECURE risk appears low based on current designation status, though the lack of transparency warrants careful evaluation.

Beijing Northland Biotech is a Chinese biotech company with extremely limited public information, presenting significant due diligence challenges for potential BD partners. The company appears to maintain a low profile with no available data on leadership, subsidiaries, or recent corporate activities. While currently clear of BIOSECURE designation, the lack of transparency and minimal corporate footprint suggests either early-stage operations or intentionally opaque structure. US pharma BD teams should exercise significant caution given the information void.

Burning Rock Biotech is a leading Chinese precision oncology company specializing in NGS-based cancer diagnostics and companion diagnostics development. The company has established partnerships with major pharma companies and maintains a clear BIOSECURE status, making it an attractive BD target for US companies seeking CDx partnerships in China. Strong commercial presence in IVD market with growing pipeline of companion diagnostics, though limited visibility into current deal-making activities due to sparse recent event data.

CANbridge Life Sciences is a Beijing/Cambridge-based biotech with dual-geography operations that appears clear of BIOSECURE designation. The company maintains a low profile with limited public information on recent corporate activities or leadership changes. Without detailed pipeline or deal history data, BD teams should approach with standard due diligence protocols while benefiting from apparent regulatory clarity.

CNBG-Virogin Biotech is a Shanghai-based biotech entity with limited public information available, making due diligence challenging. The company appears to have CNBG (China National Biotec Group) involvement based on naming, which could indicate state-owned enterprise connections. With no disclosed pipeline, key personnel, or recent deal activity, this entity presents high information opacity risks typical of early-stage Chinese biotechs. BIOSECURE risk appears low based on current designation status.

CSPC Pharmaceutical is a major Chinese integrated pharmaceutical company with strong domestic market presence and growing international ambitions. The company has demonstrated active deal-making posture with focus on innovative drugs and biosimilars, particularly in oncology and cardiovascular therapeutics. With clear BIOSECURE status, CSPC presents lower regulatory risk for US partnerships, though limited public pipeline visibility may require deeper due diligence.

CStone is a Suzhou-based immuno-oncology biotech with a commercially approved PD-L1 inhibitor (sugemalimab) in China and proven ability to execute licensing deals with Big Pharma partners like Novartis. Founded in 2015 by Frank Jiang, the company appears well-positioned for out-licensing opportunities given their clinical development capabilities and regulatory success in China. BIOSECURE risk appears low given their clear status and focus on novel drug development rather than manufacturing services.

Chia Tai Tianqing is a mid-tier Chinese pharmaceutical company headquartered in Lianyungang with clear BIOSECURE status, making it a viable partner for US pharma deals. The company operates in the competitive Chinese generics and specialty pharma market but lacks publicly available pipeline or leadership information, suggesting limited transparency or smaller scale operations. While BIOSECURE-compliant, the company's deal-making posture and therapeutic focus remain unclear due to limited public disclosure.

China Resources Sanjiu is a major Chinese pharmaceutical company listed on the Shenzhen Stock Exchange with strong financial performance, reporting revenue of ~RMB 27.6B and net profit of ~RMB 3.4B in 2024. The company is clear of BIOSECURE designation and appears to maintain strong governance standards with recent ESG reporting and independent director oversight. As a subsidiary of state-owned China Resources Group, it represents a relatively stable and compliant partner for US BD teams, though its therapeutic focus areas and pipeline depth remain unclear from available data.

Chipscreen Biosciences is a Shenzhen-based biotech company listed on Shanghai's STAR Market (688321.SS) with clear BIOSECURE status, making it a viable partner for US pharma BD teams. The company recently received clinical trial approvals for sitagliptin sodium metformin extended-release tablets and CS08399 tablets in March 2026, indicating active pipeline progression. With 2024 revenue of ¥481M but negative net profit of ¥51M, the company appears to be in a typical biotech cash-burn phase while advancing clinical programs. Recent share buyback activities suggest management confidence and potential preparation for strategic partnerships.

Connect Biopharma (CNTB) is a Taicang-based biotech with clear BIOSECURE status, making it a viable partner for US pharma deals. The company recently filed its 10-K with SEC disclosures on corporate structure and VIE arrangements, indicating ongoing US market presence and regulatory compliance. Limited public information on pipeline and recent deal activity suggests the need for direct engagement to assess partnership opportunities.

Eccogene is a Shanghai-based biotech with demonstrated partnering capability and innovative small molecule programs, evidenced by their recent ~$1B+ oral GLP-1 licensing deal with AstraZeneca. The company appears focused on metabolic diseases with strong chemistry capabilities and shows clear deal-readiness for out-licensing opportunities. BIOSECURE risk is currently low as they are not designated, making them an attractive potential partner for US pharma seeking Chinese innovation without regulatory barriers.

This appears to be erroneous data - Eli Lilly is a major US pharmaceutical company headquartered in Indianapolis, not a Chinese entity. Eli Lilly and Company is a Fortune 500 American pharmaceutical corporation founded in 1876, known for diabetes care, oncology, immunology, and neuroscience therapeutics. If evaluating partnerships with Eli Lilly's Chinese operations, BIOSECURE risk would be minimal given its US parent structure. This data requires immediate verification and correction.

Everest Medicines is a Hong Kong-listed biotech with clear BIOSECURE status, making it an attractive Chinese partner for US pharma. Under CEO Kerry Blanchard since 2023, the company has pivoted from oncology to autoimmune/renal diseases with nefecon for IgA nephropathy as a key asset in-licensed from Calliditas. Shanghai-based with strong deal-making credentials and no BIOSECURE designation concerns.

Fosun Pharma is one of China's largest pharmaceutical conglomerates with a diversified portfolio spanning drug discovery, manufacturing, and distribution. The company has an active business development strategy, particularly focused on in-licensing Western assets for the Chinese market and co-development partnerships. With clear BIOSECURE status, Fosun represents a relatively low-risk partner for US pharma companies seeking China market access. The company's strong financial position and established commercialization capabilities make it an attractive partner for licensing deals.

GSK is a major UK-based multinational pharmaceutical company with global operations and a diversified portfolio spanning pharmaceuticals, vaccines, and consumer healthcare. The company has significant presence in China through local subsidiaries and partnerships, but maintains clear BIOSECURE status with no current regulatory restrictions. GSK typically pursues strategic partnerships and licensing deals aligned with its core therapeutic focus areas including oncology, immunology, respiratory, and infectious diseases.

GenScript Biotech is a major Chinese life sciences tools and CDMO company with ~$500M revenue, best known as parent of US-listed Legend Biotech (CAR-T leader). Strong deal-making track record with global pharma partnerships for gene synthesis, biologics manufacturing, and research services. Clear BIOSECURE status reduces regulatory risk for US partnerships. Primarily a service provider rather than drug developer, making it an enabling partner for US pharma operations.

GeneScience Pharmaceuticals is a Changchun-based biotech company with clear BIOSECURE status, making it a viable partner for US pharma deals. The company operates in China's competitive biotech landscape but lacks publicly available information on recent pipeline developments or deal activity. Limited transparency on corporate structure and leadership presents due diligence challenges despite regulatory clearance.

Genetron Health is a Beijing-based biotech company listed on NASDAQ (GTH) operating in precision medicine and genomics. The company has clear BIOSECURE status, making it potentially attractive for US partnerships compared to other Chinese biotech entities. Limited public information on recent corporate activities and pipeline details suggests either a low profile or potential operational challenges that warrant deeper investigation.

Gracell Biotechnologies was a Shanghai/Suzhou-based CAR-T cell therapy company that was acquired by AbbVie for $1.2B in January 2024. The company specialized in dual-target BCMA/CD19 CAR-T therapies and has been delisted from Nasdaq following the acquisition. As Gracell is now a wholly-owned subsidiary of AbbVie, it is no longer available for independent partnerships and presents clear BIOSECURE risk mitigation through US ownership.

Guangdong Raynovent Biotech Co., Ltd is a Chinese biotech company with limited public information available, making it difficult to assess pipeline strength or deal-making posture. The company maintains clear BIOSECURE status, presenting low regulatory risk for US partnerships. However, the lack of transparency regarding leadership, corporate structure, and recent activities raises due diligence concerns. Any engagement would require extensive primary research to validate capabilities and strategic fit.

Guangdong Ruishun Biotech Co., Ltd is a Chinese biotech company with extremely limited public information available, making comprehensive evaluation challenging. The company appears to maintain a low public profile with no recorded corporate events, leadership information, or subsidiary structure disclosed. While currently clear of BIOSECURE designation, the lack of transparency and operational details presents significant due diligence challenges for potential US partnerships. Any engagement would require extensive primary research to assess pipeline, capabilities, and commercial viability.

Hangzhou Sumgen Biotech is a Chinese biotech company with limited public information available, making comprehensive due diligence challenging. While the company has clear BIOSECURE status, the lack of disclosed pipeline data, leadership information, and corporate structure details suggests either early-stage operations or limited transparency. US BD teams should exercise caution due to insufficient data for meaningful deal evaluation.

Hansoh Pharmaceutical is a major Chinese pharma company listed on Hong Kong Stock Exchange, known for its strong oncology pipeline and innovative drug development capabilities. The company has demonstrated active deal-making appetite with international partnerships and maintains a solid regulatory track record. BIOSECURE risk appears manageable as the company is not designated and has clear status, making it a viable partner for US BD teams.

Harbour BioMed is a Suzhou-based biotech company with a differentiated H2L2 fully human antibody platform using transgenic mice technology. The company has demonstrated strategic partnership capability through its AbbVie collaboration on bispecific antibodies, indicating strong deal-making credentials. With clear BIOSECURE status and Hong Kong listing, it presents lower regulatory risk for US partnerships compared to mainland Chinese biotechs.

Hengrui is China's most prolific out-licensing partner to Western pharma, with over $30B in total deal value signed since 2023. The company's July 2025 multi-asset agreement with GSK — covering 12 programs including lead asset HRS-9821 (PDE3/4 inhibitor for COPD) for $500M upfront and ~$12B in total potential value — represents the largest single China-to-West licensing transaction to date. Founded by Piaoyang Sun, who transformed it from a Lianyungang-based generics manufacturer into China's most valuable innovative pharma company, Hengrui now has 50+ clinical-stage molecules across oncology, autoimmune, metabolic, and pain. No BIOSECURE exposure — Hengrui is a drug originator, not a CDMO/CRO, and its pipeline assets are the ones being licensed, not its manufacturing capacity.

Hua Medicine is a Shanghai-based biotech focused on diabetes therapeutics, listed on HKEX (2552.HK) with clear BIOSECURE status. The company's flagship asset dorzagliatin represents a novel mechanism for diabetes treatment, positioning them as a potential licensing partner for US pharma seeking innovative metabolic disease assets. While geopolitically low-risk, limited public information on management team and corporate structure requires enhanced due diligence for any BD engagement.

Hutchmed (HCM) is a Shanghai-based biotech with a diversified oncology and immunology pipeline, trading on NASDAQ and HKEX. The company has demonstrated strong deal-making capabilities with multiple partnerships including Eli Lilly, AstraZeneca, and others, positioning it as an attractive BD target. With 'clear' BIOSECURE status, Hutchmed presents minimal regulatory risk for US partnerships. Limited available corporate intelligence suggests need for deeper due diligence on current pipeline status and leadership team.

InnoCare Pharma appears to be confused with BeiGene in this profile, as the Chinese name suggests BeiGene Beijing operations. If this is indeed a separate InnoCare entity, limited public information suggests a Beijing-based biotech with unclear corporate structure. BIOSECURE risk appears manageable given clear designation, but due diligence should verify actual corporate identity and structure. Limited visibility into pipeline and leadership raises questions about deal readiness.

Innovent is Eli Lilly's primary China biotech partner, with multiple co-development agreements covering PD-1, bispecifics, and metabolic disease. The Lilly relationship — which includes a $1B+ obesity drug deal (mazdutide/IBI362) — gives Innovent unusual validation among Western BD teams. Innovent's domestic commercial portfolio includes sintilimab (TYVYT), China's second-approved PD-1, and the company has built one of the deepest clinical pipelines among Chinese biotechs with 30+ clinical-stage programs. HKEX-listed (1801.HK) with no SEC filings, making corporate structure less transparent than dual-listed peers.

Insilico Medicine is a pioneering AI-driven drug discovery company that achieved the industry milestone of advancing the first AI-discovered drug (INS018_055) into Phase II trials for idiopathic pulmonary fibrosis. The company raised a record-breaking $787M pre-IPO round in March 2026 under the Earendil Labs brand, positioning for a potential US IPO. With clear BIOSECURE status and Hong Kong/Shanghai operations, Insilico represents a lower-risk opportunity for US pharma partnerships in the AI drug discovery space. The company appears deal-ready given its advanced pipeline and recent fundraising success.

Jacobio is a Beijing-based, Hong Kong-listed oncology biotech founded by BeiGene co-founder Yinxiang Wang, with strong credibility in RAS-targeted cancer therapies. The company has proven deal-making capability, evidenced by their successful KRAS G12C inhibitor (JAB-21822) licensing to AbbVie for ex-China rights. With clear BIOSECURE status and an experienced leadership team, Jacobio represents a lower-risk Chinese biotech partnership opportunity for US pharma. Their focus on difficult-to-drug targets like RAS proteins aligns well with major pharma strategic priorities.

Johnson & Johnson is a major US multinational pharmaceutical and medical device company headquartered in New Brunswick, NJ, with clear BIOSECURE status. As a leading Big Pharma player with extensive R&D capabilities and global reach, J&J typically pursues large-scale strategic partnerships and acquisitions. The company has strong therapeutic focus areas including oncology, immunology, and neuroscience, making it an attractive partner for innovative biotechs. Limited available data suggests this may be an incomplete profile requiring additional research.

Junshi Biosciences is a Shanghai-based oncology biotech that achieved a major milestone as the first Chinese company to secure FDA approval for a domestically-developed PD-1 antibody (toripalimab/LOQTORZI) in 2023. The company demonstrates strong deal-making capability through its successful partnership with Coherus BioSciences for US commercialization, indicating openness to strategic partnerships. With clear BIOSECURE status and proven regulatory success in both China and the US, Junshi represents a lower-risk opportunity for US pharma partnerships. The company's focus on immuno-oncology and successful navigation of FDA approval processes makes it an attractive potential partner for US BD teams seeking China-originated assets.

Kanghong Biotech (002773.SZ) is a profitable Chengdu-based biotech company with strong financial performance, reporting RMB 3.4B revenue and RMB 974M net profit in 2024. The company has demonstrated international deal-making experience through partnerships with global CROs like INC Research, suggesting readiness for cross-border collaborations. With clear BIOSECURE status, this represents a lower-risk Chinese biotech partner for US pharma companies seeking Asian market access or pipeline assets.

Kelun Pharmaceutical is a major Chinese pharmaceutical company listed on Shenzhen Stock Exchange, headquartered in Chengdu with clear BIOSECURE status. The company has historically been active in both generic drugs and innovative biologics, with particular strength in infusion solutions and oncology therapeutics. Kelun has demonstrated deal-making appetite through previous partnerships and licensing arrangements, making it a viable target for US pharma BD teams seeking China exposure without regulatory risk.

Kelun-Biotech is the innovative arm of Kelun Pharmaceutical, a leading Chinese ADC developer based in Chengdu with proven deal execution capabilities. The company demonstrated significant BD sophistication through its landmark $9.4B+ multi-ADC licensing deal with Merck, showcasing their OptiDC linker-payload platform. With clear BIOSECURE status and strong ADC expertise, they represent a low-risk, high-value partnership opportunity for US pharma seeking oncology assets.

Lee's Pharmaceutical is a Hong Kong-listed Chinese pharmaceutical company with a focus on specialty pharmaceuticals and oncology therapeutics. The company has historically been active in licensing deals and has a growing pipeline of both in-licensed and self-developed assets. With clear BIOSECURE status and Hong Kong domicile, Lee's presents lower regulatory risk for US partnerships compared to mainland Chinese entities. Limited public information on current pipeline and recent activities suggests the need for direct engagement to assess current deal opportunities.

Legend Biotech is a Nanjing-based CAR-T cell therapy company (NASDAQ: LEGN) with strong pipeline assets and established US presence through NASDAQ listing. The company appears deal-ready with proven regulatory capabilities and no current BIOSECURE designation, making it an attractive partner for US pharma BD teams. Limited recent event data suggests stable operations with standard SEC compliance for a US-listed Chinese biotech.

Livzon Pharmaceutical is a Zhuhai-based Chinese pharma company (000513.SZ) with clear BIOSECURE status, generating RMB 9.08B revenue and RMB 1.67B net profit as of 2024. The company is actively pursuing international expansion through M&A, including a public tender offer for Vietnamese company IMP, suggesting an outward-looking BD posture. Recent management changes and board resolutions indicate potential strategic shifts that could create partnering opportunities for US pharma companies.

Luye Pharma is a Hong Kong-listed Chinese pharmaceutical company headquartered in Yantai, specializing in innovative drug delivery systems and CNS therapeutics. The company has demonstrated strong commercial execution with global expansion capabilities and maintains an active BD posture for international partnerships. BIOSECURE risk appears low given clear designation status, making them a viable partner for US pharma deals. Limited public information on recent corporate activities suggests potential need for deeper due diligence on current pipeline status.

This appears to be Merck & Co., Inc. (MSD), the major US pharmaceutical company headquartered in Rahway, NJ, not a Chinese entity. As a leading global pharma with strong oncology, vaccines, and infectious disease portfolios, Merck maintains an active BD posture for both in-licensing and partnerships. BIOSECURE risk is minimal as this is a US-domiciled company, though they may have manufacturing or research operations in China that require monitoring.

Nanjing Bioheng Biotech Co., Ltd. is a Chinese biotech company with limited public information available, making due diligence challenging for potential US partners. The company appears to be a smaller, private biotech entity without significant reported pipeline activities or recent deal-making history. While currently clear of BIOSECURE designation, the lack of transparency around corporate structure and operations presents elevated compliance monitoring requirements. US BD teams should proceed with heightened due diligence given the information gaps.

Nanjing Immunophage Biotech is a Chinese biotech company with limited publicly available information, making due diligence challenging for potential US partners. The company appears to focus on immunotherapy based on its name, but pipeline details, financial status, and management team remain unclear. BIOSECURE risk appears low as the company is not currently designated, but ongoing monitoring is essential given evolving regulations. Limited transparency suggests early-stage engagement should focus on information gathering and relationship building.

Nanjing RegeneCore Biotech Co., Ltd. is a Chinese biotech company with limited public information available, presenting significant intelligence gaps for BD evaluation. The company maintains clear BIOSECURE status, eliminating immediate regulatory barriers for US partnerships. However, the absence of disclosed key personnel, pipeline data, or recent corporate activity suggests either early-stage operations or limited transparency, requiring extensive due diligence before engagement.

NovaBridge Biosciences is a Shanghai-based biotech with SEC-listed status (ticker: NBP) and clear BIOSECURE designation, making it a potentially viable Chinese partner. However, limited public information on pipeline assets, management team, and recent deal activity suggests either early-stage operations or poor disclosure practices. The company's 20-F filing indicates VIE structure typical of Chinese life sciences companies, requiring careful due diligence on actual operational control and IP ownership.

This appears to be incomplete or erroneous data, as Novartis is a major Swiss multinational pharmaceutical company headquartered in Basel, not a Chinese entity. Novartis AG is a global pharma leader with extensive R&D capabilities and active BD operations. If this refers to Novartis' Chinese operations, they maintain significant presence in China but carry no BIOSECURE risk as a Swiss-domiciled company. The lack of data suggests a data collection error requiring immediate clarification.

Ocumension Therapeutics is a Shanghai-based ophthalmology-focused biotech listed on Hong Kong Stock Exchange with clear BIOSECURE status, making it a potentially attractive Chinese partner for US pharma. The company specializes in innovative eye treatments and has shown willingness to engage in international partnerships. With no current BIOSECURE designation, Ocumension represents lower regulatory risk compared to other Chinese biotechs, though ongoing US-China tensions require monitoring. Limited public information on recent corporate activity suggests either quiet development phase or limited disclosure practices.

This appears to be incomplete or erroneous data - Pfizer is a major US pharmaceutical company headquartered in New York, not a Chinese entity. Pfizer has no BIOSECURE risk as it's an American multinational corporation. If evaluating the actual Pfizer Inc., they would be a potential partner rather than acquisition target, with strong pipeline capabilities across oncology, vaccines, and rare diseases.

RemeGen is a Hong Kong-listed Chinese biotech based in Yantai with clear BIOSECURE status, making it a relatively safe partnership target for US pharma. The company has demonstrated strong deal-making capabilities and maintains an active BD posture with multiple international partnerships. RemeGen's pipeline focuses on innovative biologics including ADCs and monoclonal antibodies across oncology and other therapeutic areas. Limited available data on recent corporate events suggests need for deeper due diligence on current pipeline status and strategic direction.

SUNHO (China) BioPharmaceutical is a Chinese biotech company with limited publicly available information, presenting significant due diligence challenges for potential US partners. While the company appears clear from current BIOSECURE designations, the lack of transparency regarding corporate structure, pipeline, and leadership raises concerns about deal readiness. US BD teams should approach with caution and expect extensive information gathering requirements before meaningful partnership discussions can proceed.

Shanghai Hengrui Pharmaceutical Co., Ltd. appears to be a subsidiary or affiliate of Jiangsu Hengrui Medicine Co., Ltd. (SHA:600276), one of China's largest pharmaceutical companies with a strong oncology and innovative drug pipeline. The company maintains clear BIOSECURE status, making it an attractive partner for US BD teams. However, limited public information on this specific subsidiary suggests it may be a smaller operating unit focused on regional Shanghai operations or specific therapeutic areas.

Shanghai Henlius Biotech is a Chinese biotech company with clear BIOSECURE status, indicating no current regulatory restrictions for US partnerships. Limited public information suggests a privately-held structure typical of emerging Chinese biotechs. Without detailed pipeline or leadership data available, thorough due diligence would be required to assess deal potential, though the clear BIOSECURE status removes a key regulatory hurdle for US BD teams.

Shanghai Kechow Pharma appears to be a relatively small or early-stage Chinese biotech company with minimal public presence and limited available information. The company's low visibility suggests either a very early-stage operation or a private entity that has not engaged in significant external partnerships. While the company shows clear BIOSECURE status, the lack of pipeline, management, or corporate structure information raises questions about deal readiness and operational maturity.

Shanghai YingLi Pharmaceutical Co. Ltd. is a Chinese biotech company with limited publicly available information, making due diligence challenging for potential partners. The company's BIOSECURE status is currently clear, presenting lower regulatory risk for US partnerships. However, the lack of transparent corporate information, pipeline details, and management visibility suggests this may be an early-stage or private entity requiring extensive due diligence. Given the information gaps, any BD engagement would need to be highly exploratory.

Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. is a Chinese biotech with extremely limited public information, presenting significant due diligence challenges for US BD teams. The company maintains clear BIOSECURE status with no designated restrictions, but the lack of disclosed management, pipeline, or corporate structure data suggests either early-stage operations or limited transparency. BD teams should approach with caution given the information opacity and prioritize comprehensive due diligence before engagement.

Simcere Pharmaceutical is a Nanjing-based pharma company listed on Hong Kong Stock Exchange with clear BIOSECURE status, making it a viable partner for US deals. The company operates in China's pharmaceutical sector but lacks publicly available detailed pipeline or recent deal activity data. With clear regulatory status and established public listing, Simcere presents moderate BD potential pending deeper pipeline assessment.

Sinovac Biotech is a Beijing-based vaccine developer best known for its COVID-19 vaccine CoronaVac, which achieved global distribution including emergency use authorizations. The company has established manufacturing capabilities and regulatory experience across multiple markets, making it an attractive partner for vaccine development and manufacturing deals. With clear BIOSECURE status, Sinovac presents lower regulatory risk for US partnerships compared to many Chinese biotech peers. The company has historically been open to licensing and partnership arrangements, particularly for global market access.

Sirnaomics is a dual-headquartered (Guangzhou/Gaithersburg) RNA therapeutics company focused on siRNA drug development, trading on NASDAQ as SIRN. The company maintains clear BIOSECURE status, positioning it favorably for US partnerships amid growing China-related regulatory scrutiny. With operations spanning both markets, Sirnaomics represents a potential bridge for cross-border collaborations in the expanding RNAi therapeutic space, though limited public disclosure on recent corporate activities suggests careful due diligence will be essential.

Structure Therapeutics is a dual-headquartered biotech (Shanghai/SF) leveraging structural biology expertise for GPCR drug discovery, with a standout oral GLP-1 program advancing to Phase II. Led by world-renowned structural biologist Raymond Stevens, the company operates through a Shanghai subsidiary but maintains clear BIOSECURE status. Strong pipeline positioning in the massive obesity/metabolic market with differentiated structural approach makes this an attractive partnership target for US pharma seeking innovative GPCR programs.

Sumitomo Pharma (Suzhou) is the Chinese subsidiary of Japanese pharmaceutical giant Sumitomo Pharma, leveraging the parent company's global R&D capabilities and market access for the Chinese market. The company benefits from clear BIOSECURE status due to its Japanese parentage, making it an attractive partner for US pharma companies seeking China exposure without regulatory risk. Limited public information suggests a focus on localized development and commercialization of Sumitomo's global portfolio, though specific pipeline details are not readily available.

Summit Therapeutics is a Miami-based biotech that pivoted from antibiotics to become Akeso's ex-China partner for ivonescimab, a PD-1/VEGF bispecific antibody. The company paid $500M upfront plus $5B in milestones for rights to what could be the first drug to beat Keytruda head-to-head in NSCLC. With a BLA filed and PDUFA date of November 2026, Summit represents a high-stakes bet on a potentially blockbuster oncology asset with clear BIOSECURE status.

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. is a Chinese biotech company with limited public information available, making due diligence challenging. The company appears to maintain a low profile with no readily accessible data on pipeline assets, recent deals, or key management personnel. While currently clear of BIOSECURE designation, the lack of transparency and corporate information raises concerns about deal readiness and partnership potential for US BD teams.

Takeda is a major Japanese multinational pharmaceutical company with dual headquarters in Tokyo and Cambridge, making it one of the largest pharma companies globally. The company has a strong deal-making posture with significant M&A activity and licensing partnerships, particularly in oncology, gastroenterology, and rare diseases. As a Japanese company with clear BIOSECURE status, Takeda presents minimal regulatory risk for US partnerships. However, the lack of available data on key personnel and recent activities suggests limited transparency or outdated intelligence.

Terns Pharmaceuticals is a dual-HQ biotech company (Foster City/Shanghai) with clear BIOSECURE status, making it a viable partner for US pharma deals. The company appears to maintain operations in both US and China, which could provide strategic advantages for global development programs. Recent 10-K filing suggests active SEC reporting and corporate governance compliance, indicating institutional-grade deal readiness.

Transcenta is a dual-listed (HK/HKEX: 6628) Chinese biotech with operations in Shanghai and Princeton, focusing on innovative biologics and oncology therapeutics. The company maintains clear BIOSECURE status and has demonstrated active deal-making capabilities with international partnerships. Strong pipeline in oncology and immunology with multiple assets in clinical development makes it an attractive BD target for US pharma seeking China exposure without regulatory complications.

Wondercel Biotech (ShenZhen) is a Chinese biotech company with extremely limited public information available, presenting significant due diligence challenges. The company appears to be a smaller, private entity with no disclosed pipeline, leadership team, or corporate activities. While currently BIOSECURE-clear, the lack of transparency and Chinese domicile requires careful risk assessment for any potential partnership.

Yisheng Biopharma (依生生物) is a Beijing-based biotech company with minimal public information available, presenting both opportunity and risk for BD evaluation. The company's BIOSECURE-clear status provides regulatory comfort for US partnerships, but the lack of transparent corporate data, pipeline information, and management visibility raises significant due diligence concerns. Without disclosed therapeutic focus areas or recent deal activity, this entity appears to be either very early-stage, privately operating below market radar, or potentially dormant.

Zai Lab is a Shanghai-based biotech that has successfully transitioned from in-licensing Western drugs for China to developing a global innovation pipeline. The company has strong deal-making capabilities, evidenced by partnerships with major pharma like Novartis and MacroGenics, and is pivoting toward out-licensing its proprietary assets globally. Key pipeline strengths include ADCs and nanobody platforms with ZL-1211 (anti-CLDN18.2 ADC) and ZL-1102 (anti-IL-17A nanobody) leading global development. BIOSECURE risk is low with clear status and no designated exposure.

Zenas BioPharma is a dual-headquartered biotech with operations in Waltham and Shanghai, positioning it at the intersection of US and Chinese markets. The company appears to be BIOSECURE-compliant with clear status, making it a viable partner for US pharma deals. Limited public information suggests a focus on maintaining regulatory compliance while developing its pipeline, though specific therapeutic areas and deal-making history require further investigation.

Zhejiang Wenda Pharma Technology LTD is a Chinese biotech company with limited publicly available information, which presents significant due diligence challenges for potential US partners. The company has clear BIOSECURE status, suggesting no current designation as a threat entity. However, the lack of disclosed key personnel, subsidiaries, or recent corporate events indicates either early-stage operations or limited transparency that warrants cautious evaluation.

Zhifei Biological is a Chongqing-based vaccine developer with strong revenue of ~$3.2B and healthy profitability, making it a potentially attractive BD partner. The company shows active pipeline development with recent approvals for mpox vaccine trials and COVID-19 mRNA vaccine studies, plus expansion into diabetes with insulin products. BIOSECURE risk appears low given its clear status, though standard due diligence on government relationships is recommended.